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Despite the consistency of these clinical data, the relationship between hsCRP and underlying atherosclerosis is complex. On the one hand, cross-sectional studies have reported no or minimal association between hsCRP levels and carotid intima-medial thickness measured by ultrasound 8, 9 or between hsCRP and total plaque burden as assessed by coronary artery calcification. 10, 11 However, hsCRP levels do associate with an increasing prevalence of thin-cap atheromas prone to plaque rupture and sudden death 12 ; correlate with more advanced luminal lesions in young persons 13 ; and positively associate with functional measures of stenosis, such as brachial artery flow-mediated responsiveness. 14 Based in part on these observations, hsCRP generally is not considered a marker for the extent of underlying atherosclerotic burden but, rather, as a marker for vulnerability and, thus, clinical events.
In this issue of Circulation: Cardiovascular Imaging, Rubin et al 15 provide additional insight into the relationship between hsCRP levels and atherosclerosis. In a thoughtful cross-sectional evaluation of 1004 asymptomatic middleaged Korean men and women who underwent coronary CT angiography (CCTA), 21% were found to have coronary plaque despite normal blood pressure, low body mass index, and lipid levels generally considered acceptable in Western settings (average LDL cholesterol, 117 mg/dL, average highdensity lipoprotein cholesterol, 60 mg/dL). Using previously validated CCTA techniques, plaques were classified as noncalcified, mixed calcified (Ͻ50% of the plaque area having a density Ͼ130 Hounsfield units), or calcified (Ͼ50% of the plaque area having density Ͼ130 Hounsfield units).
As anticipated, patients with elevated hsCRP levels had a higher prevalence of smoking, hypertension, diabetes, and hyperlipidemia. What is intriguing, however, is the manner in which hsCRP levels correlate with underlying plaque morphology as defined by CCTA. Specifically, although higher hsCRP levels were found to associate with greater total plaque burden, these associations were only significant for noncalcified and mixed-calcified plaques. By contrast, there was little if any evidence of association between hsCRP levels and fully calcified plaques. Further, the association of hsCRP level to noncalcified plaques was substantial: Compared to patients with low hsCRP levels, patients with elevated levels had a doubling of risk for noncalcified plaques after adjustment for age and sex. Thus, as seen in earlier histopathology studies and in evaluations of sudden cardiac death, the present CCTA-based study affirms that hsCRP level associates with vulnerable plaque.
The data from Rubin et al 15 confirm and extend observations from earlier investigations that demonstrated that noncalcified lesions are more likely than calcified lesions to rupture and cause clinical events, that imaging techniques can be used to detect such lesions, and that it is these vulnerable lesions that correlate best with elevated inflammatory biomarker levels. 16 -19 The current data also directly confirm work from Hausleiter and colleagues 20 Rubin et al 15 are careful to point out that CCTA is not an appropriate clinical tool for screening in primary prevention partly because of radiation exposure. Nonetheless, the current data have substantive clinical implications. First, they will add to ongoing debate surrounding whether coronary artery calcium scanning plays a useful role in primary prevention. As both Bonow 21 and O'Malley 22 have recently argued, in the absence of clear outcome data for any cardiac imaging technique in primary prevention, it is difficult to justify procedures with radiation exposure, cost, and high rates of incidental findings, particularly as we learn that calcified lesions are not the lesions of concern for our patients. It is thus imperative that the imaging community perform formal randomized trials addressing whether hard clinical outcomes improve with various forms of cardiac imaging, whether it be CCTA, coronary artery calcium scanning, or MRI.
The biomarker community has consistently performed such studies, and randomized data from the WOSCOPS (West of Scotland Coronary Prevention Study), AFCAPS/ TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study), and JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trials indicate that patients with high LDL cholesterol, low high-density lipoprotein cholesterol, or high hsCRP levels clearly benefit from statin therapy. 2, 23, 24 Thus, what the imaging community must demonstrate is (1) that in the absence of these characteristics, imaging still detects future vascular risk and (2) that patients identified by imaging benefit from a specific therapy. To date, no trials addressing these crucial issues have been initiated.
The data from Rubin et al 15 confirming close relationships between hsCRP level and vulnerable plaque also provide further support for trials directly addressing the inflammatory hypothesis of atherothrombosis. It is important to recognize that no trial has yet proven that reducing inflammation reduces vascular risk. Although multiple statin trials report greater clinical benefits when both LDL cholesterol and hsCRP levels are reduced, [25] [26] [27] [28] [29] it is impossible to deduce from these studies whether such effects are the result of lipid lowering alone or are a combined result of lipid-lowering and antiinflammatory effects. The only way to address this issue-and to close the loop on Koch postulates for the inflammatory hypothesis of atherothrombosis-is to define patient populations with a persistent inflammatory response and then randomize such patients to targeted antiinflammatory strategies that do not have confounding beneficial effects on lipids, hemostasis, or thrombosis.
We have recently initiated 1 such trial, the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS), which is designed to evaluate whether interlukin-1␤ (IL-1␤) inhibition with subcutaneous canakinumab can reduce recurrent cardiovascular events. 30 IL-1␤ inhibition represents a novel approach to antiinflammatory therapy that goes well beyond hsCRP and IL-6 reduction. Accumulating data indicate not only that cholesterol crystals serve as endogenous danger signals for the IL-1␤ producing NLRP3 inflammasome, but also that inhibition of IL-1␤ reduces atherothrombotic burden in several animal models. 31, 32 We also have proposed a second cardiovascular inflammation reduction trial in which the agent to be evaluated is low-dose methotrexate, which commonly is used for the treatment of rheumatoid arthritis. 33 In support of this alternative antiinflammatory approach is evidence from nonrandomized observational studies in patients with rheumatoid arthritis and psoriatic arthritis that patients treated with low-dose methotrexate have reduced vascular event rates.
Beyond proof of principle, the success for both the ongoing CANTOS trial and the proposed low-dose methotrexate trial will be based on the demonstration of a net clinical benefit in terms of vascular events avoided among patients exposed to these novel approaches to treatment. The use of inflammatory biomarker screening in the design of these trials will help to identify a population with a persistent inflammatory response that is most likely to benefit from antiinflammatory therapies and to exclude from randomization patients without a persistent inflammatory response and, thus, a reduced exposure risk among those least likely to benefit. As confirmed in the current study by Rubin and colleagues, 15 this biomarker screening strategy also will increase the likelihood of enrolling patients with vulnerable plaques while reducing the likelihood of enrolling those with heavily calcified lesions unlikely to rupture and less prone to sudden vessel occlusion.
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